School of Animal Science & Technology, Southwest University, Chong Qing 400715, PR China.
School of Animal Science & Technology, Southwest University, Chong Qing 400715, PR China.
Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jan 4;72:60-72. doi: 10.1016/j.pnpbp.2016.09.002. Epub 2016 Sep 7.
Accumulating evidence suggests that histone hypoacetylation which is partly mediated by histone deacetylase (HDAC), plays a causative role in the etiology of various clinical disorders such as cancer and central nervous diseases. HDAC inhibitors (HDACis) are natural or synthetic small molecules that can inhibit the activities of HDACs and restore or increase the level of histone acetylation, thus may represent the potential approach to treating a number of clinical disorders. This manuscript reviewed the progress of the most recent experimental application of HDACis as novel potential drugs or agents in a large number of clinical disorders including various brain disorders including neurodegenerative and neurodevelopmental cognitive disorders and psychiatric diseases like depression, anxiety, fear and schizophrenia, and cancer, endometriosis and cell reprogramming in somatic cell nuclear transfer in human and animal models of disease, and concluded that HDACis as potential novel therapeutic agents could be used alone or in adjunct to other pharmacological agents in various clinical diseases.
越来越多的证据表明，组蛋白去乙酰化（HDAC）介导的组蛋白低乙酰化在癌症和中枢神经系统疾病等各种临床疾病的发病机制中起因果作用。HDAC 抑制剂（HDACi）是天然或合成的小分子，可抑制 HDAC 的活性并恢复或增加组蛋白乙酰化水平，因此可能代表治疗多种临床疾病的潜在方法。本文综述了 HDACi 作为新型潜在药物或药物在大量临床疾病中的最新实验应用的进展，包括各种脑疾病，如神经退行性和神经发育性认知障碍和精神疾病，如抑郁症、焦虑症、恐惧症和精神分裂症，以及癌症、子宫内膜异位症和体细胞细胞核转移中的细胞重编程，在人类和动物疾病模型中，并得出结论，HDACi 作为潜在的新型治疗剂，可以单独使用或与其他药理学制剂联合用于各种临床疾病。
